Header Logo

Connection

NICOLA HANANIA to Asthma

Back to Details
This is a "connection" page, showing publications NICOLA HANANIA has written about Asthma.
NICOLA HANANIA
Connection Strength
25.805
Asthma
  1. A systematic review of the humanistic, economic, sociodemographic, and environmental burden of severe/difficult-to-treat asthma. Curr Med Res Opin. 2025 Jun; 41(6):1075-1095.
    View in: PubMed
    Score: 0.547
  2. Comparative effectiveness of inhaled fluticasone propionate/salmeterol and budesonide/formoterol fixed-dose combinations in asthma control - a retrospective United States database analysis. Respir Med. 2025 Aug-Sep; 245:108172.
    View in: PubMed
    Score: 0.545
  3. Influence of baseline bronchodilator reversibility and blood eosinophils on lung function in patients with asthma following omalizumab. J Allergy Clin Immunol Pract. 2024 02; 12(2):512-514.e2.
    View in: PubMed
    Score: 0.492
  4. Adding tiotropium or long-acting ?2-agonists to inhaled corticosteroids: Asthma-related exacerbation risk and healthcare resource utilization. Allergy Asthma Proc. 2023 11 13; 44(6):413-421.
    View in: PubMed
    Score: 0.490
  5. Integrating innovations in asthma research into clinical practice. Respir Med. 2023 10; 217:107345.
    View in: PubMed
    Score: 0.479
  6. Asthma and cardiovascular disease: A bidirectional association? Respirology. 2023 03; 28(3):217-219.
    View in: PubMed
    Score: 0.465
  7. Cardiovascular disease in asthma patients: From mechanisms to therapeutic implications. Kardiol Pol. 2023; 81(3):232-241.
    View in: PubMed
    Score: 0.465
  8. Is Extracorporeal Membrane Oxygenation More Than Just Salvage Therapy in Acute Life-Threatening Asthma? Chest. 2023 01; 163(1):1-2.
    View in: PubMed
    Score: 0.462
  9. Efficacy of dupilumab in patients with moderate-to-severe asthma and persistent airflow obstruction. Ann Allergy Asthma Immunol. 2023 02; 130(2):206-214.e2.
    View in: PubMed
    Score: 0.456
  10. Choosing and switching biological agents in severe asthma. Respirology. 2022 11; 27(11):926-928.
    View in: PubMed
    Score: 0.453
  11. When Asthma and Chronic Obstructive Pulmonary Disease Overlap; Current Knowledge and Unmet Needs. Immunol Allergy Clin North Am. 2022 08; 42(3):499-505.
    View in: PubMed
    Score: 0.448
  12. Pharmacologic Management Strategies of Asthma-Chronic Obstructive Pulmonary Disease Overlap. Immunol Allergy Clin North Am. 2022 08; 42(3):657-669.
    View in: PubMed
    Score: 0.448
  13. Phenotypes of Asthma-Chronic Obstructive Pulmonary Disease Overlap. Immunol Allergy Clin North Am. 2022 08; 42(3):645-655.
    View in: PubMed
    Score: 0.446
  14. Asthma-Chronic Obstructive Pulmonary Disease: An Update. Immunol Allergy Clin North Am. 2022 08; 42(3):xiii-xiv.
    View in: PubMed
    Score: 0.446
  15. Management of Life-Threatening Asthma: Severe Asthma Series. Chest. 2022 10; 162(4):747-756.
    View in: PubMed
    Score: 0.435
  16. Revisiting Mild Asthma: Current Knowledge and Future Needs. Chest. 2022 01; 161(1):26-39.
    View in: PubMed
    Score: 0.422
  17. Omalizumab in Asthma with Fixed Airway Obstruction: Post Hoc Analysis of EXTRA. J Allergy Clin Immunol Pract. 2022 01; 10(1):222-228.
    View in: PubMed
    Score: 0.420
  18. Association of Triglyceride-Glucose Index and Lung Health: A Population-Based Study. Chest. 2021 09; 160(3):1026-1034.
    View in: PubMed
    Score: 0.409
  19. Asthma and severe acute respiratory syndrome coronavirus 2019: current evidence and knowledge gaps. Curr Opin Pulm Med. 2021 01; 27(1):45-53.
    View in: PubMed
    Score: 0.402
  20. Determinants of lung function improvement with omalizumab in adults with allergic asthma. J Allergy Clin Immunol Pract. 2020 06; 8(6):2068-2070.
    View in: PubMed
    Score: 0.376
  21. Immunological biomarkers in severe asthma. Semin Immunol. 2019 12; 46:101332.
    View in: PubMed
    Score: 0.371
  22. Biological treatments for severe asthma. Curr Opin Allergy Clin Immunol. 2019 08; 19(4):379-386.
    View in: PubMed
    Score: 0.364
  23. Controversies in Allergy: Should Severe Asthma with Eosinophilic Phenotype Always Be Treated with Anti-IL-5 Therapies. J Allergy Clin Immunol Pract. 2019 May - Jun; 7(5):1430-1436.
    View in: PubMed
    Score: 0.356
  24. Targeting lipid mediators in asthma: time for reappraisal. Curr Opin Pulm Med. 2019 01; 25(1):121-127.
    View in: PubMed
    Score: 0.350
  25. Omalizumab effectiveness in asthma-COPD overlap: Post hoc analysis of PROSPERO. J Allergy Clin Immunol. 2019 04; 143(4):1629-1633.e2.
    View in: PubMed
    Score: 0.349
  26. Asthma COPD overlap: Impact of associated comorbidities. Pulm Pharmacol Ther. 2018 10; 52:27-31.
    View in: PubMed
    Score: 0.342
  27. Measurement of fractional exhaled nitric oxide in real-world clinical practice alters asthma treatment decisions. Ann Allergy Asthma Immunol. 2018 04; 120(4):414-418.e1.
    View in: PubMed
    Score: 0.332
  28. Response to omalizumab using patient enrichment criteria from trials of novel biologics in asthma. Allergy. 2018 02; 73(2):490-497.
    View in: PubMed
    Score: 0.320
  29. Predictive Biomarkers for Asthma Therapy. Curr Allergy Asthma Rep. 2017 Sep 19; 17(10):69.
    View in: PubMed
    Score: 0.320
  30. Factors associated with depressive symptoms in uncontrolled asthmatics. J Asthma. 2018 05; 55(5):555-560.
    View in: PubMed
    Score: 0.319
  31. Assessing Patient and Provider Perceptions of Factors Associated with Patient Engagement in Asthma Care. Ann Am Thorac Soc. 2017 May; 14(5):659-666.
    View in: PubMed
    Score: 0.312
  32. Revisiting Type 2-high and Type 2-low airway inflammation in asthma: current knowledge and therapeutic implications. Clin Exp Allergy. 2017 Feb; 47(2):161-175.
    View in: PubMed
    Score: 0.306
  33. Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trials. Lancet Respir Med. 2016 10; 4(10):781-796.
    View in: PubMed
    Score: 0.298
  34. Lebrikizumab in moderate-to-severe asthma: pooled data from two randomised placebo-controlled studies. Thorax. 2015 Aug; 70(8):748-56.
    View in: PubMed
    Score: 0.272
  35. The asthma COPD overlap syndrome (ACOS). Curr Allergy Asthma Rep. 2015 Mar; 15(3):509.
    View in: PubMed
    Score: 0.268
  36. Role of anticholinergics in asthma management: recent evidence and future needs. Curr Opin Pulm Med. 2015 Jan; 21(1):103-8.
    View in: PubMed
    Score: 0.265
  37. Periostin, a novel biomarker of TH2-driven asthma. Curr Opin Pulm Med. 2014 Jan; 20(1):60-5.
    View in: PubMed
    Score: 0.247
  38. Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study. Am J Respir Crit Care Med. 2013 Apr 15; 187(8):804-11.
    View in: PubMed
    Score: 0.235
  39. Asthma outcomes revisited. Curr Opin Pulm Med. 2013 Jan; 19(1):6-12.
    View in: PubMed
    Score: 0.231
  40. Targeting IgE in asthma. Curr Opin Pulm Med. 2012 Jan; 18(1):1-5.
    View in: PubMed
    Score: 0.215
  41. The effects of cigarette smoke on airway inflammation in asthma and COPD: therapeutic implications. Respir Med. 2012 Mar; 106(3):319-28.
    View in: PubMed
    Score: 0.215
  42. Asthma in the elderly: Current understanding and future research needs--a report of a National Institute on Aging (NIA) workshop. J Allergy Clin Immunol. 2011 Sep; 128(3 Suppl):S4-24.
    View in: PubMed
    Score: 0.210
  43. Omalizumab in severe allergic asthma inadequately controlled with standard therapy: a randomized trial. Ann Intern Med. 2011 05 03; 154(9):573-82.
    View in: PubMed
    Score: 0.206
  44. Vitamin D and asthma. Curr Opin Pulm Med. 2011 Jan; 17(1):1-5.
    View in: PubMed
    Score: 0.201
  45. Response to salbutamol in patients with mild asthma treated with nadolol. Eur Respir J. 2010 Oct; 36(4):963-5.
    View in: PubMed
    Score: 0.197
  46. Asthma in the elderly: current knowledge and future directions. Curr Opin Pulm Med. 2010 Jan; 16(1):55-9.
    View in: PubMed
    Score: 0.187
  47. Clinical implications of the intrinsic efficacy of beta-adrenoceptor drugs in asthma: full, partial and inverse agonism. Curr Opin Pulm Med. 2010 Jan; 16(1):1-5.
    View in: PubMed
    Score: 0.187
  48. Asthma control: a new perspective on the management of asthma. Curr Opin Pulm Med. 2009 Jan; 15(1):1-3.
    View in: PubMed
    Score: 0.175
  49. Evaluation of obstructive lung disease with vibration response imaging. J Asthma. 2008 Dec; 45(10):923-30.
    View in: PubMed
    Score: 0.174
  50. Targeting airway inflammation in asthma: current and future therapies. Chest. 2008 Apr; 133(4):989-98.
    View in: PubMed
    Score: 0.166
  51. Asthma in older adults. Clin Chest Med. 2007 Dec; 28(4):685-702, v.
    View in: PubMed
    Score: 0.162
  52. The safety and effects of the beta-blocker, nadolol, in mild asthma: an open-label pilot study. Pulm Pharmacol Ther. 2008; 21(1):134-41.
    View in: PubMed
    Score: 0.158
  53. The role of intrinsic efficacy in determining response to a beta2-agonist in acute severe asthma. Respir Med. 2007 May; 101(5):1007-14.
    View in: PubMed
    Score: 0.150
  54. Revisiting asthma control: how should it best be defined? Pulm Pharmacol Ther. 2007; 20(5):483-92.
    View in: PubMed
    Score: 0.146
  55. Influenza vaccine in patients with asthma. Expert Rev Vaccines. 2006 Feb; 5(1):111-8.
    View in: PubMed
    Score: 0.143
  56. Acute asthma in pregnancy. Crit Care Med. 2005 Oct; 33(10 Suppl):S319-24.
    View in: PubMed
    Score: 0.140
  57. Comorbidities as treatable traits of chronic airway diseases. Respir Med. 2025 Nov; 248:108333.
    View in: PubMed
    Score: 0.139
  58. The challenge of differentiating asthma from chronic obstructive pulmonary disease. Manag Care. 2005 Jul; 14(7 Suppl Obstructie Lung):9-15; discussion 24-6.
    View in: PubMed
    Score: 0.137
  59. Biologics for severe asthma: deciphering what is best for the patient. Expert Rev Clin Immunol. 2025 Aug; 21(8):1035-1054.
    View in: PubMed
    Score: 0.137
  60. Burden of Oral Corticosteroid Use in Severe Asthma: Challenges and Opportunities. Allergy. 2025 Aug; 80(8):2113-2127.
    View in: PubMed
    Score: 0.137
  61. The interplay between asthma and type 2 diabetes mellitus: mutual interactions and therapeutic implications. Expert Rev Clin Immunol. 2025 Jun; 21(6):683-699.
    View in: PubMed
    Score: 0.137
  62. Asthma in the Biologics Era: Should Oral Corticosteroid Therapy Be Relegated to History? J Allergy Clin Immunol Pract. 2025 Jul; 13(7):1559-1568.
    View in: PubMed
    Score: 0.135
  63. Inflammatory and clinical risk factors for asthma attacks (ORACLE2): a patient-level meta-analysis of control groups of 22 randomised trials. Lancet Respir Med. 2025 Jun; 13(6):505-516.
    View in: PubMed
    Score: 0.135
  64. Asthma outcomes in a safety net hospital system: A comparative study to a national cohort. Respir Med. 2025 Apr-May; 240:108032.
    View in: PubMed
    Score: 0.134
  65. The Direct and Indirect Role of IgE on Airway Epithelium in Asthma. Allergy. 2025 Apr; 80(4):919-931.
    View in: PubMed
    Score: 0.134
  66. Promoting Prevention and Targeting Remission of Asthma: A EUFOREA Consensus Statement on Raising the Bar in Asthma Care. Chest. 2025 Apr; 167(4):956-974.
    View in: PubMed
    Score: 0.132
  67. Acute asthma in pregnancy. Crit Care Clin. 2004 Oct; 20(4):731-45, x.
    View in: PubMed
    Score: 0.130
  68. Asthma and Cardiovascular Diseases: Navigating Mutual Pharmacological Interferences. Drugs. 2024 Oct; 84(10):1251-1273.
    View in: PubMed
    Score: 0.130
  69. Anti-inflammatory activities of beta2-agonists. Curr Drug Targets Inflamm Allergy. 2004 Sep; 3(3):271-7.
    View in: PubMed
    Score: 0.130
  70. Characterization of Moderate and Severe Asthma Exacerbations in the CAPTAIN Study. J Allergy Clin Immunol Pract. 2024 Sep; 12(9):2372-2380.e5.
    View in: PubMed
    Score: 0.127
  71. Immune response to influenza vaccination in children and adults with asthma: effect of corticosteroid therapy. J Allergy Clin Immunol. 2004 Apr; 113(4):717-24.
    View in: PubMed
    Score: 0.126
  72. An Update on Patient-Reported Outcomes in Asthma. Chest. 2024 05; 165(5):1049-1057.
    View in: PubMed
    Score: 0.125
  73. Lebrikizumab in Uncontrolled Asthma: Reanalysis in a Well-Defined Type 2 Population. J Allergy Clin Immunol Pract. 2024 May; 12(5):1215-1224.e3.
    View in: PubMed
    Score: 0.125
  74. Effectiveness of omalizumab across different dosing regimens in patients with moderate-to-severe allergic asthma. Respir Med. 2024 03; 223:107537.
    View in: PubMed
    Score: 0.124
  75. Tezepelumab in patients with allergic and eosinophilic asthma. Allergy. 2024 05; 79(5):1134-1145.
    View in: PubMed
    Score: 0.124
  76. Biologics in severe asthma: A pragmatic approach for choosing the right treatment for the right patient. Respir Med. 2023 11; 218:107414.
    View in: PubMed
    Score: 0.121
  77. Efficacy of dupilumab in patients with uncontrolled, moderate-to-severe asthma with fungal sensitization. Clin Exp Allergy. 2023 10; 53(10):1020-1030.
    View in: PubMed
    Score: 0.121
  78. Revisiting asthma pharmacotherapy: where do we stand and where do we want to go? Eur Respir J. 2023 08; 62(2).
    View in: PubMed
    Score: 0.120
  79. Asthma in the era of COVID-19. Respir Med. 2023 11; 218:107373.
    View in: PubMed
    Score: 0.120
  80. EUFOREA pocket guide on the diagnosis and management of asthma: An educational and practical tool for general practitioners, non-respiratory physicians, paramedics and patients. Respir Med. 2023 11; 218:107361.
    View in: PubMed
    Score: 0.120
  81. Clinic vs?Home Spirometry for Monitoring Lung Function in Patients With Asthma. Chest. 2023 11; 164(5):1087-1096.
    View in: PubMed
    Score: 0.119
  82. Questions in Mild Asthma: An Official American Thoracic Society Research Statement. Am J Respir Crit Care Med. 2023 06 01; 207(11):e77-e96.
    View in: PubMed
    Score: 0.119
  83. New insights into the pathophysiology and therapeutic targets of asthma and comorbid chronic rhinosinusitis with or without nasal polyposis. Clin Sci (Lond). 2023 05 18; 137(9):727-753.
    View in: PubMed
    Score: 0.118
  84. Dupilumab Efficacy in Patients With Uncontrolled or Oral Corticosteroid-Dependent Allergic and Nonallergic Asthma. J Allergy Clin Immunol Pract. 2023 03; 11(3):873-884.e11.
    View in: PubMed
    Score: 0.115
  85. Beta-agonist intrinsic efficacy: measurement and clinical significance. Am J Respir Crit Care Med. 2002 May 15; 165(10):1353-8.
    View in: PubMed
    Score: 0.110
  86. Dupilumab Efficacy in Steroid-Dependent Severe Asthma by Baseline Oral Corticosteroid Dose. J Allergy Clin Immunol Pract. 2022 07; 10(7):1835-1843.
    View in: PubMed
    Score: 0.110
  87. Results of a Phase 2b Trial With GB001, a Prostaglandin D2 Receptor 2 Antagonist, in Moderate to Severe Eosinophilic Asthma. Chest. 2022 08; 162(2):297-308.
    View in: PubMed
    Score: 0.109
  88. Controversies in Allergy: Choosing a Biologic for Patients with Severe Asthma. J Allergy Clin Immunol Pract. 2022 02; 10(2):410-419.
    View in: PubMed
    Score: 0.107
  89. How to Assess Effectiveness of Biologics for Asthma and What Steps to Take When There Is Not Benefit. J Allergy Clin Immunol Pract. 2021 03; 9(3):1081-1088.
    View in: PubMed
    Score: 0.102
  90. The impact of fungal allergic sensitization on asthma. Curr Opin Pulm Med. 2021 01; 27(1):3-8.
    View in: PubMed
    Score: 0.100
  91. Dual-combination maintenance inhaler preferences in asthma and chronic obstructive pulmonary disease: A patient-centered benefit-risk assessment. Respir Med. 2021 01; 176:106278.
    View in: PubMed
    Score: 0.100
  92. Efficacy and safety of once-daily single-inhaler triple therapy (FF/UMEC/VI) versus FF/VI in patients with inadequately controlled asthma (CAPTAIN): a double-blind, randomised, phase 3A trial. Lancet Respir Med. 2021 01; 9(1):69-84.
    View in: PubMed
    Score: 0.098
  93. EAACI Biologicals Guidelines-Recommendations for severe asthma. Allergy. 2021 01; 76(1):14-44.
    View in: PubMed
    Score: 0.098
  94. Biomarkers of Type 2 Airway Inflammation as Predictors of Loss of Asthma Control During Step-Down Therapy for Well-Controlled Disease: The Long-Acting Beta-Agonist Step-Down Study (LASST). J Allergy Clin Immunol Pract. 2020 Nov - Dec; 8(10):3474-3481.
    View in: PubMed
    Score: 0.097
  95. Maintenance inhaler therapy preferences of patients with asthma or chronic obstructive pulmonary disease: a discrete choice experiment. Thorax. 2020 09; 75(9):735-743.
    View in: PubMed
    Score: 0.097
  96. Efficacy of dupilumab on clinical outcomes in patients with asthma and perennial allergic rhinitis. Ann Allergy Asthma Immunol. 2020 11; 125(5):565-576.e1.
    View in: PubMed
    Score: 0.096
  97. Reducing the hidden burden of severe asthma: recognition and referrals from primary practice. J Asthma. 2021 07; 58(7):849-854.
    View in: PubMed
    Score: 0.096
  98. Efficacy and safety of treatment with biologicals (benralizumab, dupilumab and omalizumab) for severe allergic asthma: A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma. Allergy. 2020 05; 75(5):1043-1057.
    View in: PubMed
    Score: 0.096
  99. Prospective, Single-Arm, Longitudinal Study of Biomarkers in Real-World Patients with Severe Asthma. J Allergy Clin Immunol Pract. 2020 09; 8(8):2630-2639.e6.
    View in: PubMed
    Score: 0.096
  100. Staphylococcus aureus and its IgE-inducing enterotoxins in asthma: current knowledge. Eur Respir J. 2020 04; 55(4).
    View in: PubMed
    Score: 0.095
  101. Efficacy and safety of treatment with dupilumab for severe asthma: A systematic review of the EAACI guidelines-Recommendations on the use of biologicals in severe asthma. Allergy. 2020 05; 75(5):1058-1068.
    View in: PubMed
    Score: 0.095
  102. Design of a home-based intervention for Houston-area African-American adults with asthma: Methods and lessons learned from a pragmatic randomized trial. Contemp Clin Trials. 2020 04; 91:105977.
    View in: PubMed
    Score: 0.095
  103. Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma. Allergy. 2020 05; 75(5):1023-1042.
    View in: PubMed
    Score: 0.095
  104. Precision medicine and treatable traits in chronic airway diseases - where do we stand? Curr Opin Pulm Med. 2020 01; 26(1):33-39.
    View in: PubMed
    Score: 0.094
  105. Dupilumab Efficacy in Patients with Uncontrolled, Moderate-to-Severe Allergic Asthma. J Allergy Clin Immunol Pract. 2020 02; 8(2):516-526.
    View in: PubMed
    Score: 0.092
  106. Omalizumab Treatment Patterns Among Patients with Asthma in the US Medicare Population. J Allergy Clin Immunol Pract. 2020 02; 8(2):507-515.e10.
    View in: PubMed
    Score: 0.091
  107. Impact of doxofylline compared to theophylline in asthma: A pooled analysis of functional and clinical outcomes from two multicentre, double-blind, randomized studies (DOROTHEO 1 and DOROTHEO 2). Pulm Pharmacol Ther. 2018 Dec; 53:20-26.
    View in: PubMed
    Score: 0.086
  108. Effect of exposure to low levels of ozone on the response to inhaled allergen in allergic asthmatic patients. Chest. 1998 Sep; 114(3):752-6.
    View in: PubMed
    Score: 0.085
  109. Clinical Approach to the Therapy of Asthma-COPD Overlap. Chest. 2019 01; 155(1):168-177.
    View in: PubMed
    Score: 0.085
  110. How does race/ethnicity influence pharmacological response to asthma therapies? Expert Opin Drug Metab Toxicol. 2018 Apr; 14(4):435-446.
    View in: PubMed
    Score: 0.083
  111. Targeting the interleukin-4 and interleukin-13 pathways in severe asthma: current knowledge and future needs. Curr Opin Pulm Med. 2018 01; 24(1):50-55.
    View in: PubMed
    Score: 0.082
  112. Controversies and opportunities in severe asthma. Curr Opin Pulm Med. 2018 01; 24(1):83-93.
    View in: PubMed
    Score: 0.082
  113. Care pathways for the selection of a biologic in severe asthma. Eur Respir J. 2017 12; 50(6).
    View in: PubMed
    Score: 0.081
  114. Step-Down Therapy for Asthma Well Controlled on Inhaled Corticosteroid and Long-Acting Beta-Agonist: A Randomized Clinical Trial. J Allergy Clin Immunol Pract. 2018 Mar - Apr; 6(2):633-643.e1.
    View in: PubMed
    Score: 0.080
  115. Role of biologics targeting type 2 airway inflammation in asthma: what have we learned so far? Curr Opin Pulm Med. 2017 01; 23(1):3-11.
    View in: PubMed
    Score: 0.076
  116. Fungal Sensitization Is Associated with Increased Risk of Life-Threatening Asthma. J Allergy Clin Immunol Pract. 2017 Jul - Aug; 5(4):1025-1031.e2.
    View in: PubMed
    Score: 0.076
  117. An Official American Thoracic Society Workshop Report: Evaluation and Management of Asthma in the Elderly. Ann Am Thorac Soc. 2016 11; 13(11):2064-2077.
    View in: PubMed
    Score: 0.075
  118. Characteristics and outcomes of older adults with long-standing versus late-onset asthma. J Asthma. 2017 04; 54(3):223-229.
    View in: PubMed
    Score: 0.074
  119. Assessing biomarkers in a real-world severe asthma study (ARIETTA). Respir Med. 2016 06; 115:7-12.
    View in: PubMed
    Score: 0.072
  120. Role of T2 inflammation biomarkers in severe asthma. Curr Opin Pulm Med. 2016 Jan; 22(1):59-68.
    View in: PubMed
    Score: 0.071
  121. Dose-related decrease in bone density among asthmatic patients treated with inhaled corticosteroids. J Allergy Clin Immunol. 1995 Nov; 96(5 Pt 1):571-9.
    View in: PubMed
    Score: 0.070
  122. IgE-mediated asthma: New revelations and future insights. Respir Med. 2016 Mar; 112:128-9.
    View in: PubMed
    Score: 0.070
  123. Health-care utilization after near-fatal asthma. Chest. 1995 Jun; 107(6):1564-9.
    View in: PubMed
    Score: 0.068
  124. Antifungals in severe asthma. Curr Opin Pulm Med. 2015 Jan; 21(1):48-54.
    View in: PubMed
    Score: 0.066
  125. Omalizumab in asthma: an update on recent developments. J Allergy Clin Immunol Pract. 2014 Sep-Oct; 2(5):525-36.e1.
    View in: PubMed
    Score: 0.064
  126. Blocking KV1.3 channels inhibits Th2 lymphocyte function and treats a rat model of asthma. J Biol Chem. 2014 May 02; 289(18):12623-32.
    View in: PubMed
    Score: 0.063
  127. Bronchial thermoplasty: Long-term safety and effectiveness in patients with severe persistent asthma. J Allergy Clin Immunol. 2013 Dec; 132(6):1295-302.
    View in: PubMed
    Score: 0.060
  128. Age-related differences in asthma outcomes in the United States, 1988-2006. Ann Allergy Asthma Immunol. 2013 Apr; 110(4):240-6, 246.e1.
    View in: PubMed
    Score: 0.058
  129. Age-related differences in clinical outcomes for acute asthma in the United States, 2006-2008. J Allergy Clin Immunol. 2012 May; 129(5):1252-1258.e1.
    View in: PubMed
    Score: 0.054
  130. Lebrikizumab treatment in adults with asthma. N Engl J Med. 2011 Sep 22; 365(12):1088-98.
    View in: PubMed
    Score: 0.052
  131. Persistence of effectiveness of bronchial thermoplasty in patients with severe asthma. Ann Allergy Asthma Immunol. 2011 Jul; 107(1):65-70.
    View in: PubMed
    Score: 0.051
  132. beta-Adrenoceptor inverse agonists in asthma. Curr Opin Pharmacol. 2010 Jun; 10(3):254-9.
    View in: PubMed
    Score: 0.048
  133. Beta2-adrenoceptor signaling is required for the development of an asthma phenotype in a murine model. Proc Natl Acad Sci U S A. 2009 Feb 17; 106(7):2435-40.
    View in: PubMed
    Score: 0.044
  134. Comparison of levalbuterol and racemic albuterol in hospitalized patients with acute asthma or COPD: a 2-week, multicenter, randomized, open-label study. Clin Ther. 2008; 30 Spec No:989-1002.
    View in: PubMed
    Score: 0.041
  135. Predicting episodes of poor asthma control in treated patients with asthma. J Allergy Clin Immunol. 2006 Dec; 118(6):1226-33.
    View in: PubMed
    Score: 0.038
  136. A comparison of levalbuterol with racemic albuterol in the treatment of acute severe asthma exacerbations in adults. Am J Emerg Med. 2006 May; 24(3):259-67.
    View in: PubMed
    Score: 0.036
  137. Ventilation of patients with asthma and obstructive lung disease. Crit Care Clin. 1998 Oct; 14(4):685-705.
    View in: PubMed
    Score: 0.021
  138. Potential Risks Related to Modulating Interleukin-13 and Interleukin-4 Signalling: A Systematic Review. Drug Saf. 2018 05; 41(5):489-509.
    View in: PubMed
    Score: 0.021
  139. Factors Determining In Vitro Lung Deposition of Albuterol Aerosol Delivered by Ventolin Metered-Dose Inhaler. J Aerosol Med Pulm Drug Deliv. 2017 Aug; 30(4):256-266.
    View in: PubMed
    Score: 0.019
  140. New perspectives regarding ?(2) -adrenoceptor ligands in the treatment of asthma. Br J Pharmacol. 2011 May; 163(1):18-28.
    View in: PubMed
    Score: 0.013
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.